MYQORZO shows strong early sales and market expansion potential for Cytokinetics in HCM treatment.
Cytokinetics' drug MYQORZO is gaining rapid market access with over 30% new-to-brand share and strong prescriber adoption, indicating solid commercial momentum beyond initial revenue reports. Clinical trials MAPLE-HCM and ACACIA-HCM suggest MYQORZO c...
